The role of intralesional therapies in melanoma

ONCOLOGY (United States)

Volumn 30, Issue 5, 2016, Pages

  Agarwala, Sanjiv S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; IPILIMUMAB; TALIMOGENE LAHERPAREPVEC; VELIMOGENE ALIPLASMID;

ARTICLE; CANCER SURVIVAL; ELECTROPORATION; ENTEROVIRUS; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNE RESPONSE; INTRALESIONAL DRUG ADMINISTRATION; LYMPH NODE METASTASIS; MAJOR HISTOCOMPATIBILITY COMPLEX; METASTATIC MELANOMA; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN DEFECT; SYSTEMIC DISEASE;

EID: 84968754237     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. National Institutes of Health. SEER stat fact sheets: melanoma of the skin. http://seer.cancer.gov/statfacts/html/melan.html. Accessed April 1, 2016.
2. Thompson JF. Local and regional therapies for melanoma: many arrows in the quiver. J Surg Oncol. 2014;109:295.
3. Goldie JH. Scientific basis for adjuvant and primary (neoadjuvant) chemotherapy. Semin Oncol. 1987;14:1-7.
4. Weiss DW. MER and other mycobacterial fractions in the immunotherapy of cancer. Med Clin North Am. 1976;60:473-97.
5. Dummer R, Rochlitz C, Velu T, et al. Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid tumors and melanoma. Mol Ther. 2008;16:985-94.
6. Morton DL, Eilber FR, Holmes EC, et al. BCG immunotherapy of malignant melanoma: summary of a seven-year experience. Ann Surg. 1974;180:635-43.
7. de la Monte SM, Hutchins GM. Fatal disseminated bacillus Calmette-Guerin infection and arrested growth of cutaneous malignant melanoma following intralesional immunotherapy. Am J Dermatopathol. 1986;8:331-5.
8. Agarwala SS, Neuberg D, Park Y, Kirkwood JM. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer stage I-III melanoma (E1673). Cancer. 2004;100:1692-8.
9. Garrido C, Paco L, Romero I, et al. MHC class I molecules act as tumor suppressor genes regulating the cell cycle gene expression, invasion and intrinsic tumorigenicity of melanoma cells. Carcinogenesis. 2012;33:687-93.
10. Bedikian AY, Richards J, Kharkevitch D, et al. A phase 2 study of high-dose allovectin-7 in patients with advanced metastatic melanoma. Melanoma Res. 2010;20:218-26.
11. Andtbacka RHI, Gonzalez R, Wloch MK, et al. A phase 3 clinical trial to evaluate the safety and efficacy of treatment with 2 mg intralesional Allovectin-7® compared to dacarbazine (DTIC) or temozolomide (TMZ) in subjects with recurrent metastatic melanoma. 10th International Meeting of the Society for Melanoma Research; 2013 Nov 18; Philadelphia, PA.
12. Daud A, Algazi P, Ashworth MT, et al. Systemic antitumor effect and clinical response in a phase 2 trial of intratumoral electroporation of plasmid interleukin-12 in patients with advanced melanoma. American Society of Clinical Oncology 2014 Annual Meeting; 2014 May 30–Jun 3; Chicago, IL. Abstr 9025.
13. Kaufman HL, Andtbacka RHI, Collichio FA, et al. Primary overall survival from OPTiM, a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of unresected stage IIIB/C and IV melanoma. American Society of Clinical Oncology 2014 Annual Meeting; 2014 May 30–Jun 3; Chicago, IL. Abstr 9008a.
14. Andtbacka RH, Ross MI, Delman K, et al. Responses of injected and uninjected lesions to intralesional talimogene laherparepvec (T-VEC) in the OPTiM study and the contribution of surgery to response. Society of Surgical Oncology 67th Annual Meeting; 2015 Mar 12–15; Phoenix, AZ. Abstr 52.2015.
15. Wachter EA, Dees C, Harkins J, et al. Functional imaging of photosensitizers using multiphoton microscopy. Proc. SPIE. 2002;4620:143.
16. Agarwala SS, Thompson JF, Smithers BM, et al. Immuno-hemoablation of metastatic melanoma with intralesional Rose Bengal (PV-10). European Society for Medical Oncology 2012 Annual Meeting; 2012 Sep 28–Oct 2; Vienna, Austria. Abstr 1137P.
17. Agarwala SS, Thompson JF, Smithers BM, et al. Efficacy of intralesional Rose Bengal in patients receiving injection of all existing melanoma in phase II study PV-10-MM-02. American Society of Clinical Oncology 2014 Annual Meeting; 2014 May 30–Jun 3; Chicago, IL. Abstr 9027.
18. Agarwala S. PV-10. 2nd European Post-Chicago Melanoma Meeting; 2012 Jun 21–22; Munich, Germany. https://www.pvct.com/news/PV-10_Second-PostASCO-22Jun2012.pdf. Accessed April 1, 2016.
19. US National Institutes of Health. PV-10 vs chemotherapy or oncolytic viral therapy for treatment of locally advanced cutaneous melanoma. https://clinicaltrials.gov/ct2/show/NCT02288897. Accessed April 1, 2016.
20. Andtbacka RHI, Curti B, Kaufman H, et al. CALM study: secondary endpoints of a phase II study of a novel oncolytic immunotherapeutic agent, coxsackievirus A21, delivered intratumorally in patients with advanced malignant melanoma. Ann Oncol. 2014;25(suppl 4):4374-4393.
21. Andtbacka RHI, Curti BD, Hallmeyer S, et al. Phase II CALM extension study: Coxsackievirus A21 delivered intratumorally to patients with advanced melanoma induces immune-cell infiltration in the tumor microenvironment. J Immunother Cancer. 2015;3(suppl 2):P343.
22. Promising strategy for advanced melanoma: intralesional therapies plus systemic immunotherapies. Cancer Watch. 2014;23:186-7.
23. Puzanov I, Milhem MM, Andtbacka RHI, et al. Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. J Clin Oncol. 2014;32(suppl 5s):abstr 9029.
24. Ribas A, Puzanov I, Gajewski T, et al. A multicenter, open-label trial of talimogene laherparepvec (T-VEC) plus pembrolizumab vs pembrolizumab monotherapy in previously untreated, unresected, stage IIIB-IV melanoma. J Clin Oncol. 2015;33(suppl):abstr TPS9081.
25. Fuerst ML. T-VEC plus pembrolizumab combo shows activity in advanced melanoma. http://www.cancernetwork.com/smr-2015/t-vec-plus-pembrolizumab-combo-shows-activityadvanced-melanoma. Accessed April 1, 2016.
26. Curti B, Richards J, Faries M, et al. Phase 1b study of a novel immunotherapy combination therapy of intralesional Coxsackievirus A21 and systemic ipilimumab in patients with advanced melanoma. American Association for Cancer Research 2016 Annual Meeting; 2016 Apr 16–20; New Orleans, LA. Abstr CT021.
27. Provectus Biopharmaceuticals, Inc. Provectus Biopharmaceuticals confirms first patients dosed in trials of PV-10 for melanoma. https://www.pvct.com/pressrelease.html?article=20160112.1. Accessed April 1, 2016.
28. US National Institutes of Health. Efficacy and safety of talimogene laherparepvec neoadjuvant treatment plus surgery versus surgery alone for melanoma. https://clinicaltrials.gov/ct2/show/NCT02211131. Accessed April 1, 2016.